On October 5, 2022 Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target solid tumors, reported that the SITC (Free SITC Whitepaper) abstract review committee has selected the ONCOS-102 phase 1b study in PD-1 resistant advanced melanoma for oral presentation at the annual meeting to be held in November in Boston (Press release, Targovax, OCT 5, 2022, View Source [SID1234621726]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PD-1 checkpoint inhibitor (CPI) resistant advanced melanoma is a major unmet medical need affecting up to 25,000 patients per year in the major markets. The diagnosis is associated with a poor prognosis and there are currently no approved treatment options available.

In an earlier topline data release from this Phase 1b study, Targovax reported an encouraging objective response rate (ORR) of 35% for the combination of ONCOS-102 and the PD-1 CPI Keytruda. At the SITC (Free SITC Whitepaper) conference, further translational biomarker analyses and the impact of dosing regimen on systemic activity and immune responses will be presented.

Title of the abstract, to be presented both orally and as a poster:

Presenter: Dr. Alexander Shoushtari, Principal Investigator, Memorial Sloan Kettering Cancer Center, NYC
Title: Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (r/r) melanoma
Date: 10 November, 2022
Time: 7pm ET
Dr. Lone Ottesen, Chief Medical Officer of Targovax ASA, said: "It is a great honor to have our study selected for an oral presentation at the SITC (Free SITC Whitepaper) annual meeting, which is considered the most prestigious scientific forum in cancer immunotherapy. The podium presentation will be given by principal investigator Dr. Alexander Shoushtari from the Memorial Sloan Kettering Cancer Center in New York, and provides an excellent opportunity to showcase the strong ONCOS-102 melanoma data package to a broad, international audience of academic leaders".

On October 5, 2022 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, reported it will present two posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, being held in Boston, MA from November 8 – 12, 2022 (Press release, Sensei Biotherapeutics, OCT 5, 2022, View Source [SID1234621725]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Title: Functional characterization of the inhibitory activity and identification of novel T-cell receptors for the tumor-associated macrophage receptor VSIG4
Presentation Type: Poster
Abstract Number: 485
Date and Time: Thursday, November 10, 2022 at 9:00 a.m. ET – 9:00 p.m. ET
Location: Boston Convention and Exhibition Center

Title: SNS-101, a highly pH-selective VISTA:PSGL-1 inhibitory antibody, potentiates anti-PD-1 sensitivity, expands memory T-cells and enhances tumor infiltration of CD8 T-cells
Presentation Type: Poster
Abstract Number: 856
Date and Time: Friday, November 11, 2022 at 9:00 a.m. ET – 9:00 p.m. ET
Location: Boston Convention and Exhibition Center

On October 5, 2022 Translational Drug Development (TD2), a precision oncology contract research organization (CRO), reported the addition of Dr. Alan Miller as their new Chief Medical Officer (Press release, Research Corporation Tech, OCT 5, 2022, View Source [SID1234621724]). Prior to joining TD2, Dr. Miller was Chief Medical Director of Oncology and Associate Chief Medical Director of Clinical Research at SCL Health.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Miller obtained his Ph.D. at Roswell Park (SUNY) and his M.D. from the University of Miami School of Medicine. Trained as a medical oncologist, he was also the Associate Senior Vice President for Health Sciences for Tulane Cancer Center, where he navigated the challenges of rebuilding and re-establishing the university and hospital following Hurricane Katrina. He also served as Cancer Center Director of the Baylor Sammons Cancer Center where he brought together a not-for-profit healthcare system and private oncology practices to form an oncology network across north Texas. Additionally, Dr. Miller built a larger system-wide oncology network while at SCL Health and established a system-wide clinical trials infrastructure for a multi-state healthcare system. He also serves as a Board Member for the American Cancer Society Denver and Rocky Mountain Oncology Society.

"Dr. Miller has extensive experience across many cancer types and new medicine development." said Dr. Stephen Gately, President, and CEO of TD2. "He will be an incredible resource to both our internal teams, as well as clients, as we continue our strategic growth."

On October 5, 2022 Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, reported that a team of scientists at Prestige Biopharma Innovative Discovery Centre (IDC) published a study titled ‘PAUF Induces Migration of Human Pancreatic Cancer Cells Exclusively via the TLR4/MyD88/NF‐κB Signalling Pathway’ in the International Journal of Molecular Sciences (Press release, Prestige BioPharma, OCT 5, 2022, View Source [SID1234621723]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PAUF (pancreatic adenocarcinoma up‐regulated factor) is a novel secreted protein which is substantially expressed in pancreatic cancer cells. It is known to induce pancreatic cancer progression and metastasis. According to this study, PAUF binds directly to TLR4 (Toll‐like receptor 4), which is identified as a receptor for PAUF, on pancreatic cancer cell surfaces and promote cell migration exclusively through the TLR4/MyD88/NF‐κB pathway.

In addition, the study demonstrated that the knockout of TLR4 led to a marked decrease in the expression of PD‐L1 (Programmed Death‐Ligand 1), an immune checkpoint contributing to cancer immune escape. Accordingly, the scientists are conducting a follow-up study to confirm if combining anti-PAUF treatment with TLR4 inhibitor can enhance treatment efficacy.

The results of this study enhanced the understanding of the mechanism of PAUF‐induced tumour‐promoting effects. Furthermore, it suggests that TLR4 expression on cancer cells may be a critical biomarker for anti‐PAUF treatment, implying a potential clinical application in later phase clinical trials.

Prestige Biopharma has been developing PBP1510 (INN: Ulenistamab), a first-in-class anti-PAUF monoclonal antibody for pancreatic cancer treatment. PBP1510 been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA), US Food and Drug Administration (FDA) and Korean MFDS. Currently, it is on Phase 1/2a clinical trial in France, Spain, and US.

Sangseok Koh, President of Prestige Biopharma IDC commented: "Through this study, we found a potential therapeutic biomarker and target for the development of effective pancreatic cancer treatment. We will keep up our research to discover and develop methods to control TLR4 expression and further improve PBP1510’s treatment effect."

Meanwhile, Prestige Biopharma IDC is also undergoing research on technology for diagnosis of pancreatic cancer by detecting PAUF in the body. IDC aims to continue its efforts to enable early diagnosis of fatal diseases as well as effective treatment through innovative drugs.

On October 5, 2022 OncoNano Medicine, Inc. reported it will be presenting data on two development candidates, as well as its ON-BOARD delivery platform, at the 37th Annual Meeting of the Society for Immunology of Cancer (SITC) (Free SITC Whitepaper), taking place November 8-12, 2022 in Boston, Massachusetts (Press release, OncoNano Medicine, OCT 5, 2022, View Source [SID1234621722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An oral and poster presentation by Dr. Qiang Feng detail new pre-clinical data for ONM-405, an IL-2-Fc construct formulated with OncoNano’s proprietary ON-BOARD polymeric-micelle delivery system. OncoNano’s lead clinical candidate, pegsitacianine, currently in Phase 2 clinical trials, is formulated with ON-BOARD. The ON-BOARD platform is designed to carry oncology intervention payloads systemically to the tumor microenvironment, minimizing systemic exposure and toxicity.

OncoNano will also present a poster detailing data from studies involving the use of the ON-BOARD platform for encapsulation and delivery of bispecific T cell engagers. In addition, a poster will feature new preclinical data of ONM-501, a novel dual-activating polyvalent STING (STimulator of INterferon Genes) agonist for immuno-oncology applications.